Kempharm Z Score
KMPH   USA Stock  USD 10.99 0.23 2.14% 
Kempharm Z Score Analysis
Kempharm's ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2020  2021 (projected)  
Interest Expense  4.79 M  4.75 M 
Gross Profit  13.29 M  14.56 M 
Z Score  =  Sum Of   5 Factors 
Current Kempharm Z Score  61.0 
Most of Kempharm's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kempharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Kempharm Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Kempharm is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Kempharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kempharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kempharm's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
Based on the company's disclosures, Kempharm has a Z Score of 61. This is much higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The z score for all United States stocks is notably lower than that of the firm.
Kempharm Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kempharm's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kempharm could also be used in its relative valuation, which is a method of valuing Kempharm by comparing valuation metrics of similar companies.Kempharm is currently under evaluation in z score category among related companies.
Kempharm Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kempharm from analyzing Kempharm's financial statements. These drivers represent accounts that assess Kempharm's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kempharm's important valuation drivers and their relationship over time.
2016  2017  2018  2019  2020  2021 (projected)  
Average Assets  99 M  64.11 M  30.53 M  14.07 M  10.91 M  11.19 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (10.85 M)  (37.32 M)  (50.8 M)  (19.38 M)  (7.74 M)  (8.35 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (10.85 M)  (37.32 M)  (50.8 M)  (19.38 M)  (7.74 M)  (8.35 M)  
Earnings before Tax  (16.53 M)  (43.43 M)  (56.59 M)  (24.54 M)  (12.79 M)  (13.8 M)  
Average Equity  (9.91 M)  (44.71 M)  (81.28 M)  (75.36 M)  (65.07 M)  (70.21 M)  
Enterprise Value  112.15 M  142.95 M  135.37 M  85.21 M  114.02 M  118.94 M  
Free Cash Flow  (30.41 M)  (33.28 M)  (54.22 M)  (23.76 M)  (1.97 M)  (2.13 M)  
Invested Capital  152.37 M  122.46 M  77.67 M  81.05 M  69.7 M  76.98 M  
Invested Capital Average  147.93 M  137.1 M  92.2 M  76.47 M  19.55 M  20.07 M  
Market Capitalization  43.21 M  59.36 M  47.09 M  12.6 M  50.78 M  61.81 M  
Tangible Asset Value  84.89 M  52.46 M  26.75 M  10.51 M  11.21 M  11.5 M  
Working Capital  67.72 M  34.39 M  11.72 M  1.54 M  846 K  868.26 K 
Kempharm Fundamentals
Return On Equity  (222.16) %  
Return On Asset  6.45 %  
Profit Margin  (74.21) %  
Operating Margin  21.98 %  
Current Valuation  328.5 M  
Shares Outstanding  28.51 M  
Shares Owned by Insiders  14.73 %  
Shares Owned by Institutions  16.03 %  
Number of Shares Shorted  3.55 M  
Price to Earning  (1.21) X  
Price to Book  3.64 X  
Price to Sales  13.16 X  
Revenue  23.32 M  
Gross Profit  11.98 M  
EBITDA  5.39 M  
Net Income  (54.75 M)  
Cash and Equivalents  75.92 M  
Cash per Share  2.66 X  
Total Debt  2.75 M  
Debt to Equity  0.032 %  
Current Ratio  20.70 X  
Book Value Per Share  2.96 X  
Cash Flow from Operations  (2.5 M)  
Short Ratio  6.11 X  
Earnings Per Share  (6.83) X  
Number of Employees  22  
Beta  3.36  
Market Capitalization  306.74 M  
Total Asset  54.59 M  
Retained Earnings  (252.18 M)  
Working Capital  45.74 M  
Current Asset  54.08 M  
Current Liabilities  8.34 M  
Z Score  61.0 
About Kempharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kempharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kempharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kempharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Kempharm Investors Sentiment
The influence of Kempharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Kempharm. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Please see Kempharm Piotroski F Score and Kempharm Valuation analysis. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Kempharm Stock analysis
When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device  Go  
Performance AnalysisCheck effects of meanvariance optimization against your current asset allocation  Go  
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities  Go  
Price TransformationUse Price Transformation models to analyze depth of different equity instruments across global markets  Go  
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins  Go  
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing  Go 
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.